Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
35 hedge funds and large institutions have $176M invested in Syros Pharmaceuticals, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and closing their positions.
192% more funds holding
Funds holding: 12 → 35 (+23)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
15% less capital invested
Capital invested by funds: $207M → $176M (-$30.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.08M |
| 2 |
JP Morgan Chase
New York
|
+$1.73M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.58M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$807K |
| 5 |
AIC
AWM Investment Company
New York
|
+$604K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aisling Capital
New York
|
-$5.08M |
| 2 |
DM
Deerfield Management
New York
|
-$3.58M |
| 3 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$1.14M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$678K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BIT
26
BlackRock Institutional Trust
San Francisco,
California
| $90K | +$82K | +646 | New |
|
|
TA
27
Teachers Advisors
New York
| $68K | +$62.6K | +493 | New |
|
|
BIM
28
BlackRock Investment Management
Wilmington,
Delaware
| $34K | +$31K | +244 | New |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| $21K | +$19.5K | +154 | New |
|
|
SO
30
STRS Ohio
Columbus,
Ohio
| $20K | +$19K | +150 | New |
|
31
Barclays
London,
United Kingdom
| $5K | +$4.7K | +37 | New |
|
32
Citigroup
New York
| $5K | +$4.82K | +38 | New |
|
33
BNP Paribas Financial Markets
Paris,
France
| $2.3K | +$2.16K | +17 | New |
|
34
Creative Planning
Overland Park,
Kansas
| $2K | +$2.29K | +18 | New |
|
35
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$1.27K | +10 | New |
|
SYRS Hedge Fund Activity: Q3 2016 in Review
35 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q3 2016, worth a combined $176M — down 15% from $207M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new SYRS positions and 0 closed out — a net gain of 24 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $6.08M. The largest seller was Aisling Capital, cutting an estimated $5.08M.
- 35 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q3 2016, up from 12 in Q2 2016.
- Funds reported $176M of Syros Pharmaceuticals, Inc. Common Stock stock for Q3 2016, down 15% quarter-over-quarter.
- 24 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q3 2016 and 0 closed out, a net change of +24 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q3 2016 was Fidelity Investments, an estimated $6.08M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q3 2016 was Aisling Capital, an estimated $5.08M sold.
Based on aggregated 13F filings for Q3 2016.